Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026

Compugen (NASDAQ: CGEN; TASE: CGEN) will release its second quarter 2026 financial results on Monday, August 3, 2026, before U.S. markets open, and will host a conference call and webcast at 8:30 AM ET to review results and provide a corporate update.

Rhea-AI Summary

Compugen (NASDAQ: CGEN; TASE: CGEN) will release its second quarter 2026 financial results on Monday, August 3, 2026, before U.S. markets open, and will host a conference call and webcast at 8:30 AM ET to review results and provide a corporate update.

Investors can join by dialing 1-866-744-5399 in the U.S. or +972-3-918-0644 internationally, or via live webcast on Compugen’s website, where a replay will also be available. Compugen is a clinical-stage cancer immunotherapy company leveraging its AI/ML Unigen platform and developing assets including COM701, rilvegostomig and GS-0321 in collaboration with partners such as AstraZeneca and Gilead.

Argus Jul 20 session 8 alerts

-1.27% close to close 0.9x rel. volume Open Argus

Details

News Market Reaction – CGEN

+3.3% Peak in 4 hr 8 min

$224.17M Mkt Cap at Peak Alert

On Jul 20, the day this news came out, CGEN closed 1.27% below the previous close. Argus tracked a peak move of +3.3% during that session. Our momentum scanner recorded 8 alerts in the available session data.

Data tracked by StockTitan Argus for the Jul 20 session.

Key Figures

Results period: Second quarter 2026 Release date: August 3, 2026 Conference call time: 8:30 AM ET +2 more

Results period

Second quarter 2026

Scheduled financial results release

Release date

August 3, 2026

Before U.S. financial markets open

Conference call time

8:30 AM ET

Management review and corporate update

Rilvegostomig development phases

Phase 3, Phase 2 and Phase 1

Multiple clinical trials

GS-0321 development phase

Phase 1

Clinical trial conducted by Compugen

Previous Earnings date Reports

2 past events · Latest: May 04

Same Type 2 events

1. May 04

   Q1 earnings date

   24h Move

   -2.6%

   Scheduled first-quarter results release and management conference call

2. Feb 17

   Q4 earnings date

   24h Move

   +1.8%

   Scheduled fourth-quarter and full-year results release before market open

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

adaptive platform trial, bispecific antibody, maintenance therapy, phase 3

4 terms

adaptive platform trial medical

"evaluated in a blinded randomized ovarian cancer adaptive platform trial"

An adaptive platform trial is a flexible clinical study design that tests multiple treatments at once and adjusts which drugs, doses, or patient groups are pursued as results come in. Think of it like a single kitchen testing several recipes and quickly favoring the ones that work while dropping or changing the others — this can speed development, cut costs, and reduce risk for investors by identifying winners and failures faster than traditional one-at-a-time trials.

bispecific antibody medical

"a PD-1/TIGIT bispecific antibody"

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

maintenance therapy medical

"as a single agent in maintenance therapy"

Treatment given after an initial successful response to control a chronic or recurring disease and prevent it from returning or worsening; it often involves lower-intensity, ongoing medication or interventions rather than aggressive cures. For investors, maintenance therapy matters because it can create steady, long-term demand for drugs or services, similar to a subscription that generates predictable revenue and extends a product’s commercial life beyond the initial treatment period.

phase 3 medical

"being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOLON, Israel, July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2026 financial results on Monday, August 3, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link.

Following the live webcast, a replay will be available on the Company's website.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company Contact:

Lindsey Trickett
Head of Investor Relations and Corporate Communications
Email: lindseyt@cgen.com
Tel: +1 (628) 241-0071

 

View original content:https://www.prnewswire.com/news-releases/compugen-to-release-second-quarter-2026-results-on-monday-august-3-2026-302829393.html

SOURCE Compugen Ltd.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Compugen (CGEN) release its Q2 2026 financial results?

Compugen will release its second quarter 2026 financial results on Monday, August 3, 2026, before U.S. markets open. According to Compugen, the release will be followed by a conference call and webcast at 8:30 AM ET for investors and analysts.

What time is Compugen (CGEN) Q2 2026 earnings conference call and webcast?

Compugen’s Q2 2026 conference call and webcast is scheduled for 8:30 AM ET on August 3, 2026. According to Compugen, management will review the quarter’s financial results and provide a corporate update during this call for investors and other interested parties.

How can investors access the Compugen (CGEN) Q2 2026 earnings call by phone?

Investors can access Compugen’s Q2 2026 earnings call by dialing 1-866-744-5399 from the U.S. or +972-3-918-0644 internationally. According to Compugen, these numbers connect to the live conference line at 8:30 AM ET on August 3, 2026.

Will there be a webcast and replay for Compugen (CGEN) Q2 2026 results?

Yes, Compugen will provide a live webcast of the Q2 2026 call through its website, with a replay available afterwards. According to Compugen, investors can access both the live and archived webcast via the company’s online investor relations section.

What does Compugen (CGEN) do in cancer immunotherapy?

Compugen is a clinical-stage cancer immunotherapy company using its AI/ML Unigen platform to discover drug targets. According to Compugen, its pipeline includes COM701, rilvegostomig and GS-0321, evaluated in various clinical trials, some under license agreements with AstraZeneca and Gilead.

Which key drug candidates are in Compugen’s (CGEN) clinical pipeline?

Compugen’s clinical pipeline includes COM701, rilvegostomig and GS-0321. According to Compugen, COM701 is studied in ovarian cancer maintenance therapy, while rilvegostomig and GS-0321 are being developed under license agreements with AstraZeneca and Gilead, respectively.